ALGS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
27.8M
+881.6%
2.8M
+1574.6%
169.0K
-77.2%
741.0K
-23.2%
965.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
27.8M
+881.6%
2.8M
+1574.6%
169.0K
-77.2%
741.0K
-23.2%
965.0K
Operating Expenses
29.7M
-0.3%
29.8M
+35.4%
22.0M
-24.5%
29.1M
+49.0%
19.5M
R&D
24.1M
+3.0%
23.4M
+37.1%
17.0M
-28.8%
23.9M
+71.3%
14.0M
SG&A
5.6M
-12.3%
6.4M
+29.6%
4.9M
-4.3%
5.2M
-7.0%
5.6M
Operating Income
-1890000
+93.0%
-26929000
-23.4%
-21814000
+23.1%
-28361000
-52.7%
-18567000
EBITDA
-1635000
+93.8%
-26583000
-23.3%
-21557000
+23.4%
-28141000
-53.7%
-18308000
Net Income
-1504000
+93.5%
-23040000
-15.9%
-19881000
+37.0%
-31537000
-98.8%
-15863000
EPS (Basic)
$-0.14
+93.7%
$-2.21
-15.7%
$-1.91
+37.2%
$-3.04
-98.7%
$-1.53
EPS (Diluted)
$-0.14
+93.7%
$-2.21
-12.2%
$-1.97
+35.2%
$-3.04
-98.7%
$-1.53
Shares (Diluted)
10.4M
+0.3%
10.4M
+2.9%
10.1M
-2.5%
10.4M
+0.2%
10.4M
Aligos Therapeutics (ALGS) โ€” Financials